Tapahtumakalenteri

syyskuu 18

Studia Medicina: Suolistosyöpä yleistyy mutta ennuste paranee

Suolistosyöpä yleistyy mutta ennuste paranee

professori Perttu Arkkila HY/HUS Suolistosyövän seulonnan avulla varhaisempaan diagnoosiin

Osastonylilääkäri, dosentti Anna Lepistö HY/HUS Suolistosyövän hoito tänään

professori emerita Helena Isoniemi HY/HUS: Etäpesäke maksassa – onko potilaalla toivoa?

Puheenjohtajana toimii erikoislääkäri, dosentti Johanna Louhimo HY/HUS
Aloitusaika: 18.09.2024 17:00
Lopetusaika: 18.09.2024 19:00
Kesto: 1 hour
Sijainti: Biomedicum1, lecture hall 1, Haartmaninkatu 8, 00290 Helsinki
Tyyppi: Seminar
Organisaatio: Biomedicum Helsinki Foundation
Yhteyshenkilö: saatio@biomedicum.fi
syyskuu 20

Seminar by Associate Professor Yoshifumi Itoh

MT1-MMP: A cell surface metalloproteinase that modulates cellular microenvironment

Short biography:

After receiving his Msc in Pharmaceutical Sciences from Tokyo College of Pharmacy in Japan, in 1991 Dr Itoh moved to the University of Kansas Medical Center, USA to work with Prof Hideaki Nagase.

 

Using his research outcomes, he received a PhD from the Tokyo University of Pharmacy and Life Sciences, Japan, in 1996. In 1997 he became an Assistant Professor in Prof Motoharu Seiki's department at the Institute of Medical Sciences, University of Tokyo.

 

In 2001 he then moved to the Kennedy Institute of Rheumatology, Imperial College London to run his own lab and relocated to Oxford when the Kennedy Institute joined the University of Oxford.

 

His major scientific interests have been centered on mechanisms of cellular invasion and tissue destruction, especially in the aspects of arthritis and cancer, as they share common mechanisms and pathways.

 

Selected publications

1.   Itoh Y (2022) Proteolytic modulation of tumor microenvironment signals during cancer progression. Front Oncol, 12, 935231

2.   Gifford V, Woskowicz A, Ito N, Balint S, Lagerholm BC, Dustin ML, Itoh Y (2022) Coordination of two kinesin superfamily motor proteins, KIF3A and KIF13A, is essential for pericellular matrix degradation by membrane-type 1 matrix metalloproteinase (MT1-MMP) in cancer cells. Matrix Biology, 107, 1-23. 

3.   Itoh Y, Ng M, Wiberg A, Inoue K, Hirata N, Paiva KBS, Ito N, Dzobo K, Sato N, Gifford V, Fujita Y, Inada M, and Furniss D, (2021) A common SNP risk variant MT1-MMP causative for Dupuytren's Disease has a specific defect in collagenolytic activity. Matrix Biol, 97, 20-39.

4.   Kaneko K, Williams RO, Dransfield DT, Nixon AE, Sandison A and Itoh Y (2016) Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of inflammatory arthritis: synergy with TNF blockade. Arthritis Rheum 68 (2), 521-531 

5.   Woskowicz AM, Weaver SA, Shitomi Y, Ito N, Itoh Y. (2013) MT-LOOP-dependent localization of MT1-MMP to the cell adhesion complexes promotes cancer cell invasion. J Biol Chem. 288, 35126-37.



Aloitusaika: 20.09.2024 10:00
Lopetusaika: 20.09.2024 11:00
Kesto: 1 hour
Sijainti: Biomedicum 1, seminar room 3
Tyyppi: Seminar
Organisaatio: UH, Faculty of Medicine
Yhteyshenkilö: paivi.ojala@helsinki.fi
syyskuu 20

Kliinisen mikrobiologian perjantaisarja

Jätevesien mikrobianalytiikka avaa uusia mahdollisuuksia tartuntatautien seurantaan väestötasolla
Tarja Pitkänen, johtava asiantuntija, Vesimikrobiologian laboratorio THL ja apulaisprofessori
Helsingin yliopiston eläinlääketieteellinen tiedekunta  

Aloitusaika: 20.09.2024 12:00
Lopetusaika: 20.09.2024 13:00
Kesto:
Sijainti: HUSLAB talo, 4 krs, Jälki G4101
Tyyppi: Seminar
Organisaatio: HUS
Yhteyshenkilö: juulia.suominen@hus.fi
syyskuu 25

FICAN webinar by prof Kimmo Porkka

Advancing cancer care with real-world data

professor Kimmo Porkka
Department of Oncology, University of Helsinki and
HUS 
Helsinki University Hospital

Organized by FICAN South
Aloitusaika: 25.09.2024 15:00
Lopetusaika: 25.09.2024 16:00
Kesto:
Sijainti: remotely
Tyyppi: Webinar
Organisaatio: Finnish Cancer Center (FICAN)
Yhteyshenkilö: outi.nikunen@hus.fi
lokakuu 29

Navigating from Biomarker Discovery to Clinical Trial

Do you have a promising biomarker that you're eager to validate in a clinical trial? Join us as we explore the journey from biomarker discovery to clinical trial execution, providing valuable insights and practical guidance for researchers and clinicians.

Target Audience: Scientists and clinicians interested in initiating and executing investigator-initiated biomarker trials.



Aloitusaika: 29.10.2024 14:15
Lopetusaika: 29.10.2024 18:15
Kesto: 3 hours
Sijainti: Biomedicum1, lecture hall 2, Haartmaninkatu 8, 00290 Helsinki
Tyyppi: Other
Organisaatio: FIMM
Yhteyshenkilö: mika.kontro@helsinki.fi